Ultrasmall Oxygen-Deficient Bimetallic Oxide MnWO Nanoparticles for Depletion of Endogenous GSH and Enhanced Sonodynamic Cancer Therapy.

Fei Gong,Liang Cheng,Nailin Yang,Oshra Betzer,Liangzhu Feng,Qiang Zhou,Yonggang Li,Ruihua Chen,Rachela Popovtzer,Zhuang Liu

DOI: https://doi.org/10.1002/adma.201900730

IF: 29.4

2019-01-01

Advanced Materials

Abstract:Sonodynamic therapy (SDT) triggered by ultrasound (US) has attracted increasing attention owing to its abilities to overcome critical limitations including low tissue-penetration depth and phototoxicity in photodynamic therapy. Herein, the design of a new type of sonosensitizer is revealed, namely, ultrasmall oxygen-deficient bimetallic oxide MnWOX nanoparticles, for multimodal imaging-guided enhanced SDT against cancer. As-made MnWOX nanoparticles with poly(ethylene glycol) (PEG) modification show high physiological stability and biocompatibility. Interestingly, such MnWOX-PEG nanoparticles exhibit highly efficient US-triggered production of O-1(2) and center dot OH, higher than that of previously reported sonosensitizers (e.g., protoporphyrin IX and titanium dioxide), because the oxygen-deficient structure of MnWOX serves as an electron trap site to prevent electron-hole recombination. The glutathione depletion capability of MnWOX-PEG can also further favor SDT-triggered cancer cell killing. With efficient tumor homing as illustrated by computer tomography and magnetic resonance imaging, MnWOX-PEG enables effective destruction of mouse tumors under US stimulation. After accomplishing its therapeutic functions, MnWOX-PEG can be metabolized by the mouse body without any long-term toxicity. Herein, a new type of sono-sensitizing agent with high SDT efficacy, multimodal imaging functions, and rapid clearance is presented, an agent which is promising for noninvasive SDT cancer treatment.